{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:58:30Z","timestamp":1785308310907,"version":"3.55.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Liver metastasis is associated with reduced benefit from immune checkpoint inhibitors (ICIs) in several gastrointestinal cancers, yet the background liver status is rarely considered in immunotherapy biomarker studies. Here, we examine whether metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) may alter the immune environment of liver metastases and affect ICI efficacy. The available evidence is strongest, and most mechanistic, for colorectal liver metastasis and derives largely from preclinical models; it is emerging for pancreatic ductal adenocarcinoma and limited for gastric and biliary tract cancers. MASLD and MASH should not be treated as interchangeable: simple steatosis, active steatohepatitis, fibrosis, and cirrhosis represent distinct liver conditions with different possible effects on hepatic seeding and immune-cell access. Early steatohepatitic inflammation may promote hepatic colonization through lipid availability, hepatocyte stress, and myeloid-cell recruitment, whereas advanced fibrosis can reduce initial colonization while impairing lymphocyte access to established lesions. ICI efficacy requires viable tumor-reactive T cells, relief from myeloid-cell suppression, and direct tumor-T-cell contact; MASLD- and MASH-related liver changes may interfere with each of these requirements through mechanisms beyond checkpoint-ligand expression alone. We distinguish T-cell exhaustion from liver metastasis-associated T-cell deletion, and highlight macrophage-mediated elimination of tumor-specific CD8-positive T cells, myeloid chemokine signaling-driven suppressor-cell recruitment, and stromal remodeling as candidate mechanisms, supported mainly by preclinical evidence, that may reduce ICI response. These mechanisms remain unvalidated as predictors of ICI response in cohorts with MASLD\/MASH staging. Future studies should assess liver fat, inflammatory activity, fibrosis stage, tumor genotype, and ICI outcomes in the same patients to test whether MASLD\/MASH stage is associated with differential benefit.<\/jats:p>","DOI":"10.3389\/fnut.2026.1878927","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:40Z","timestamp":1785304720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic dysfunction-associated steatotic liver disease and immune checkpoint inhibitor response in gastrointestinal liver metastases: current evidence and future directions"],"prefix":"10.3389","volume":"13","author":[{"given":"Shilin","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital of Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital of Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital of Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital of Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery, General Surgery, Qilu Hospital of Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","article-title":"Liver metastases","volume":"7","author":"Tsilimigras","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1002\/hep.21060","article-title":"The liver as an immunological organ","volume":"43","author":"Racanelli","year":"2006","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e2346094","DOI":"10.1001\/jamanetworkopen.2023.46094","article-title":"Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal cancer: a secondary analysis of a randomized clinical trial","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"651086","DOI":"10.3389\/fimmu.2021.651086","article-title":"Pan-Cancer analysis identifies liver metastases as negative predictive factor for immune checkpoint inhibitors treatment outcome","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101125","DOI":"10.1016\/j.drup.2024.101125","article-title":"Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance","volume":"77","author":"Dong","year":"2024","journal-title":"Drug Resist Updat"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"ref11","first-page":"1159","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume-title":"Cell Mol Immunol","author":"He","year":"2025"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2010.10.005","article-title":"Liver antigen-presenting cells","volume":"54","author":"Crispe","year":"2011","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/hep.27254","article-title":"Immune tolerance in liver disease","volume":"60","author":"Crispe","year":"2014","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10585-023-10217-7","article-title":"Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis","volume":"40","author":"Tian","year":"2023","journal-title":"Clin Exp Metastasis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3332\/ecancer.2024.1771","article-title":"Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review","volume":"18","author":"Aruquipa","year":"2024","journal-title":"Ecancermedicalscience"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1158\/1078-0432.ccr-22-2041","article-title":"Colorectal Cancer metastases in the liver establish immunosuppressive spatial networking between tumor-associated SPP1+ macrophages and fibroblasts","volume":"29","author":"Sathe","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to Cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e136215","DOI":"10.1172\/jci.insight.136215","article-title":"Hepatic lipids promote liver metastasis","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41420-023-01770-x","article-title":"Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.cmet.2023.04.013","article-title":"Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment","volume":"35","author":"Wang","year":"2023","journal-title":"Cell Metab"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.jcmgh.2024.04.008","article-title":"Concomitant NAFLD facilitates liver metastases and PD-1-refractory by recruiting MDSCs via CXCL5\/CXCR2 in colorectal Cancer","volume":"18","author":"Yang","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat Metab"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/hep.30693","article-title":"NOD-like receptor C4 Inflammasome regulates the growth of Colon Cancer liver metastasis in NAFLD","volume":"70","author":"Ohashi","year":"2019","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e0491","DOI":"10.1097\/HC9.0000000000000491","article-title":"Liver macrophages revisited: the expanding universe of versatile responses in a spatiotemporal context","volume":"8","author":"Guillot","year":"2024","journal-title":"Hepatol Commun"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ncb3169","article-title":"Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver","volume":"17","author":"Costa-Silva","year":"2015","journal-title":"Nat Cell Biol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41392-025-02562-8","article-title":"Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis","volume":"11","author":"Yu","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metab"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-020-2394-6","article-title":"DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25","volume":"583","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e180802","DOI":"10.1172\/JCI180802","article-title":"Metastatic tumor growth in steatotic liver is promoted by HAS2-mediated fibrotic tumor microenvironment","volume":"135","author":"Yang","year":"2025","journal-title":"J Clin Invest"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s12029-024-01042-6","article-title":"Non-alcoholic fatty liver disease may be a risk factor for liver metastasis after radical surgery for colorectal cancer: a retrospective study","volume":"55","author":"Miyata","year":"2024","journal-title":"J Gastrointest Cancer"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fonc.2020.00251","article-title":"Effect of non-alcoholic fatty liver disease on the risk of synchronous liver metastasis: analysis of 451 consecutive patients of newly diagnosed colorectal Cancer","volume":"10","author":"Lv","year":"2020","journal-title":"Front Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2353\/ajpath.2009.080703","article-title":"High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model","volume":"175","author":"VanSaun","year":"2009","journal-title":"Am J Pathol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12885-021-07980-9","article-title":"Baseline liver steatosis has no impact on liver metastases and overall survival in rectal cancer patients","volume":"21","author":"Besutti","year":"2021","journal-title":"BMC Cancer"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.62347\/jhms4303","article-title":"Hepatic steatosis predicts metachronous liver metastasis in colorectal cancer patients: a nested case-control study and systematic review","volume":"14","author":"Dai","year":"2024","journal-title":"Am J Cancer Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e108618","DOI":"10.1371\/journal.pone.0108618","article-title":"Patients with chronically diseased livers have lower incidence of colorectal liver metastases: a meta-analysis","volume":"9","author":"Cai","year":"2014","journal-title":"PLoS One"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/s1072-7515(03)00117-0","article-title":"Colorectal adenocarcinoma in cirrhotic patients","volume":"196","author":"Gervaz","year":"2003","journal-title":"J Am Coll Surg"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00384-013-1656-2","article-title":"Hepatic steatosis is associated with lower incidence of liver metastasis from colorectal cancer","volume":"28","author":"Murono","year":"2013","journal-title":"Int J Color Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/bjc.2016.155","article-title":"The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer","volume":"115","author":"Kondo","year":"2016","journal-title":"Br J Cancer"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ejso.2022.11.002","article-title":"Inhibitory effect of non-alcoholic steatohepatitis on colon cancer liver metastasis","volume":"49","author":"Yamada","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/bjc.2017.334","article-title":"International consensus guidelines for scoring the histopathological growth patterns of liver metastasis","volume":"117","author":"van Dam","year":"2017","journal-title":"Br J Cancer"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41416-022-01859-7","article-title":"Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights","volume":"127","author":"Latacz","year":"2022","journal-title":"Br J Cancer"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41416-020-0881-z","article-title":"Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis","volume":"123","author":"H\u00f6ppener","year":"2020","journal-title":"Br J Cancer"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41416-020-0812-z","article-title":"Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases","volume":"122","author":"Stremitzer","year":"2020","journal-title":"Br J Cancer"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00262-020-02632-6","article-title":"Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy","volume":"69","author":"Liang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41416-021-01667-5","article-title":"Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns","volume":"126","author":"Messaoudi","year":"2022","journal-title":"Br J Cancer"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"pkab026","DOI":"10.1093\/jncics\/pkab026","article-title":"Histopathological growth patterns and survival after resection of colorectal liver metastasis: an external validation study","volume":"5","author":"H\u00f6ppener","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1053\/j.gastro.2022.11.029","article-title":"Integrated multi-omics landscape of liver metastases","volume":"164","author":"Yang","year":"2023","journal-title":"Gastroenterology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"e007235","DOI":"10.1136\/jitc-2023-007235","article-title":"Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer","volume":"11","author":"Akce","year":"2023","journal-title":"J Immunother Cancer"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10637-023-01410-2","article-title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","volume":"42","author":"Armstrong","year":"2024","journal-title":"Investig New Drugs"},{"key":"ref65","volume-title":"A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies","year":"2026"},{"key":"ref66","volume-title":"An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","year":"2026"},{"key":"ref67","volume-title":"A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer","year":"2026"},{"key":"ref68","volume-title":"Phase I\/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)","year":"2026"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2159-8290.cd-21-0316","article-title":"Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","article-title":"Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease","volume":"1","author":"Boyle","year":"2019","journal-title":"JHEP Rep"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1878927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:42Z","timestamp":1785304722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1878927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":70,"alternative-id":["10.3389\/fnut.2026.1878927"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1878927","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1878927"}}